NCT06868732View on ClinicalTrials.gov

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

December 30, 2028

Conditions
Advanced Non-small Cell Lung Cancer
Interventions
DRUG

JSKN016

Administered intravenously according to protocol.

DRUG

Carboplatin

AUC 4, Q3W, administered intravenously according to protocol.

DRUG

Furmonertinib Mesylate

160mg, qd, administered according to protocol.

DRUG

Ivonescimab

20mg/kg, Q3W, administered intravenously according to protocol.

DRUG

Docetaxel

60mg/m\^2, Q3W, administered intravenously according to protocol.

DRUG

Tislelizumab

200mg, Q3W, administered intravenously according to protocol.

DRUG

Pembrolizumab

200mg, Q3W, administered intravenously according to protocol.

All Listed Sponsors
lead

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY